LTS:0QYW (Canada)
Business Description
Bausch Health Companies Inc
NAICS : 325412
SIC : 3741
2150 Saint Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Compare
Compare
Traded in other countries / regions
BHC.Canada
•
BVF.Germany
•
BHC.Mexico
•
VRX.Switzerland
•
0QYW.UK
•
BHC.USA
Description
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.05 | |||||
| Equity-to-Asset | -0.01 | |||||
| Debt-to-Equity | -107.26 | |||||
| Debt-to-EBITDA | 9.61 | |||||
| Interest Coverage | 0.69 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 0.04 | |||||
| Beneish M-Score | -2.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -2.1 | |||||
| 3-Year EBITDA Growth Rate | 73.3 | |||||
| 3-Year EPS without NRI Growth Rate | 40.3 | |||||
| 3-Year FCF Growth Rate | -5.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 1.36 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.22 | |||||
| Quick Ratio | 1 | |||||
| Cash Ratio | 0.26 | |||||
| Days Inventory | 161.8 | |||||
| Days Sales Outstanding | 71.72 | |||||
| Days Payable | 65.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.9 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 71.53 | |||||
| Operating Margin % | 11.8 | |||||
| Net Margin % | -4.66 | |||||
| ROA % | -1.31 | |||||
| ROIC % | 2.79 | |||||
| ROC (Joel Greenblatt) % | 58.54 | |||||
| ROCE % | 3.8 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 6.61 | |||||
| PS Ratio | 0.25 | |||||
| Price-to-Free-Cash-Flow | 3.25 | |||||
| Price-to-Operating-Cash-Flow | 2.28 | |||||
| EV-to-EBIT | 25.65 | |||||
| EV-to-EBITDA | 9.79 | |||||
| EV-to-Revenue | 2.85 | |||||
| EV-to-FCF | 37.1 | |||||
| Price-to-Projected-FCF | 0.17 | |||||
| Price-to-Median-PS-Value | 0.22 | |||||
| Earnings Yield (Greenblatt) % | 3.9 | |||||
| Forward Rate of Return (Yacktman) % | 69.7 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 7,659.516 | ||
| EPS (TTM) (CHF) | -1.029 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (CHF) | 0 | ||
| 20-Day SMA (CHF) | 122.93991 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (CHF) | 122.93991 - 122.93991 | ||
| Shares Outstanding (Mil) | 361.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bausch Health Companies Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||